Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6[J]. Chest, 1989, 96: 68-73.
[1]
Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis [J]. Am J Respir Crit Care Med, 2006, 174(7): 810-816.
[2]
Kim D S, Collard H R, King T E Jr. Classification and natural history of the idiopathic interstitial pneumonias [J]. Proc Am Thorac Soc, 2006, 3(4): 285-292.
[8]
Hesselstrand R, Wildt M, Bozovic G, et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis [J]. Respir Med, 2013, 107(7): 1079-1086.
Ryerson C J, Hartman T, Elicker B M, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis [J]. Chest, 2013, 144(1): 234-240.
[10]
Huang H, Peng X, Nakajima J. Adances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan [J]. Biosci Trends, 2013, 7(4): 172-177.
[4]
Raghu G, Collard H R, Egan J J, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management [J]. Am J Respir Crit Care Med, 2011, 183(6): 788-824.
Ishii H, Mukae H, Kadota J, et al. High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia [J]. Thorax, 2003,58:52-54.
[12]
Nobuhisa I, Noboru H, Akihito Y,et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases [J]. Respir Investig, 2012, 50(1): 3-13.
[6]
Ichiyasu H, Ichikado K, Yamashita A, et al. Pneumocyte biomarkers KL-6 and surfactant protein D reflect the distinct findings of high-resolution computed tomography in nonspecific interstitial pneumonia [J]. Respiration, 2012,83:190-197.
[13]
Shukla M N, Rose J L, Ray R, et al. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7 [J]. Am J Respir Cell Mol Biol, 2009, 40(6): 643-653.
[14]
Xu L, Yan D R, Zhu S L, et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation [J]. Eur Rev Med Pharmacol Sci, 2013, 17(22): 3073-3077.
Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6[J]. Chest, 1989, 96: 68-73.
[17]
Du C, Yang Y, Lin Y, et al. Expression and mechanism of BRP-39 in bleomycin-induced pulmonary fibrosis in rat [J]. Cell Biochem Biophys, 2014, 70(1): 251-257.
[8]
Hesselstrand R, Wildt M, Bozovic G, et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis [J]. Respir Med, 2013, 107(7): 1079-1086.
Furuhashi K, Suda T, Nakamura Y, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis [J]. Respir Med, 2010, 104: 1204-1210.
[10]
Huang H, Peng X, Nakajima J. Adances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan [J]. Biosci Trends, 2013, 7(4): 172-177.
Samukawa T, Hamada T, Uto H, et al. The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D [J]. BMC Pulm Med, 2012, 12: 55-62.
[12]
Nobuhisa I, Noboru H, Akihito Y,et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases [J]. Respir Investig, 2012, 50(1): 3-13.
[20]
Song J W, Do K H, Jang S J, et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis [J]. Chest, 2013, 143(5): 1422-1429.
[13]
Shukla M N, Rose J L, Ray R, et al. Hepatocyte growth factor inhibits epithelial to myofibroblast transition in lung cells via Smad7 [J]. Am J Respir Cell Mol Biol, 2009, 40(6): 643-653.
[14]
Xu L, Yan D R, Zhu S L, et al. KL-6 regulated the expression of HGF, collagen and myofibroblast differentiation [J]. Eur Rev Med Pharmacol Sci, 2013, 17(22): 3073-3077.
[21]
Zhang H, Wang R, Wang H, et al. Dynamic changes in expression of clara cell protein and surfactant protein-D expressions in lung tissues and bronchoalveolar lavage fluid of silica-treated rats [J]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, 2014, 32(3): 168-172.
Woenckhaus M, Merk J, Stoehr R, et al. Prognostic value of FHIT, CTNNBI and MUC1 expression in non-small cell lung cancer [J]. Hum Pathol, 2008, 39(1): 126-136.
Du C, Yang Y, Lin Y, et al. Expression and mechanism of BRP-39 in bleomycin-induced pulmonary fibrosis in rat [J]. Cell Biochem Biophys, 2014, 70(1): 251-257.
[24]
Them I, Andritzky B, Schuch G, et al. Elevated pre-treatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic non-small cell lung cancer [J]. Cancer, 2010, 116(17): 4114-4121.
[18]
Furuhashi K, Suda T, Nakamura Y, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis [J]. Respir Med, 2010, 104: 1204-1210.
[19]
Samukawa T, Hamada T, Uto H, et al. The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D [J]. BMC Pulm Med, 2012, 12: 55-62.
[20]
Song J W, Do K H, Jang S J, et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis [J]. Chest, 2013, 143(5): 1422-1429.
[21]
Zhang H, Wang R, Wang H, et al. Dynamic changes in expression of clara cell protein and surfactant protein-D expressions in lung tissues and bronchoalveolar lavage fluid of silica-treated rats [J]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, 2014, 32(3): 168-172.
Woenckhaus M, Merk J, Stoehr R, et al. Prognostic value of FHIT, CTNNBI and MUC1 expression in non-small cell lung cancer [J]. Hum Pathol, 2008, 39(1): 126-136.
[24]
Them I, Andritzky B, Schuch G, et al. Elevated pre-treatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic non-small cell lung cancer [J]. Cancer, 2010, 116(17): 4114-4121.